Terumo Europe N.V., a global leader in cardiovascular surgery technologies, announced MDR certification for the CDI OneView™ Monitoring System. This next-generation CDI Systems platform provides visibility of key patient parameters during cardiopulmonary bypass surgery, critical to perfusion safety and improving medical outcomes.
The new CDI OneView™ Monitoring System monitors and displays up to 22 key parameters of patients, the newest of which are: measured flow (Q), cardiac index (CI), regional cerebral oxygen saturation (rSO2), oxygen extraction ratio (O2ER), Area Under the DO2 Curve (AUC), and measured arterial oxygen saturation (SaO2).
This innovative system offers maximum configurability and flexibility in how the parameters can be viewed and prioritized to best suit clinical needs and preferences, while continuing to provide the critical information in real time about the patient, on which clinicians have come to rely.
“In today's cardiac care landscape, data is more than numbers—it's insight, precision, and ultimately, better outcomes for patients. The CDI OneView™ Monitoring System represents a significant step forward in empowering perfusionists and clinicians with real-time, actionable data," said Sebastien van den Berghe, Vice President Terumo Cardiovascular EMEA & Sales North America. “At Terumo, we believe that continuous innovation in monitoring is essential to improving clinical decision-making and elevating the standard of care across EMEA and beyond".
New features and functions of Terumo's latest patient parameter monitoring system were influenced by extensive perfusionist input from leading global cardiovascular institutions. In response to the growing needs of healthcare providers, the new CDI OneView™ Monitoring System now provides several Goal Directed Therapy parameters: real-time O2ER, CI, VO2 and DO2 information to help perfusionists maintain a safe threshold for those parameters. Independently published and reviewed clinical research indicates that maintaining optimal levels during cardiopulmonary bypass can help to reduce the incidence of acute kidney injury and hyperlactatemia.1, 2
- Oshita, T et al. A Better Predictor of Acute Kidney Injury After Cardiac Surgery: The Largest Area Under the Curve Below the Oxygen Delivery Threshold During Cardiopulmonary Bypass. J Am Heart Assoc. 2020;9: e015566. DOI: 10.1161/JAHA.119.015566.
- Condello, I, et al. Association between oxygen delivery and cardiac index with hyperlactatemia during cardiopulmonary bypass. JTCVS Techniques. 2020; Vol 2: 92-99.
For more information contact us
Email: Cardiovascular.EMEA@terumo-europe.com
About Terumo Cardiovascular
Terumo Cardiovascular manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass and intra-operative monitoring. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Asia, and Latin America. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiovascular surgery specialties. https://www.terumocv.com
About Terumo Europe
Terumo Europe N.V. is a core player in the EMEA healthcare market by providing best-in-class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets, and sells a vast range of medical devices in five main business units: Interventional Systems, Pharmaceutical Solutions, Hospital Care Solutions, Cardiovascular and Life Care Solutions. www.terumo-europe.com
About Terumo
Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of “Contributing to Society through Healthcare." Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions. https://www.terumo.com/
©Terumo Europe N.V. CV479GB 09.25 TCV-I(09.25)E. Company names and brand names used herein/hereon are trademarks or registered trademarks of TERUMO CORPORATION, its affiliates, or unrelated third parties.
